Your browser doesn't support javascript.
loading
Detection of brain somatic variation in epilepsy-associated developmental lesions.
Bedrosian, Tracy A; Miller, Katherine E; Grischow, Olivia E; Schieffer, Kathleen M; LaHaye, Stephanie; Yoon, Hyojung; Miller, Anthony R; Navarro, Jason; Westfall, Jesse; Leraas, Kristen; Choi, Samantha; Williamson, Rachel; Fitch, James; Kelly, Benjamin J; White, Peter; Lee, Kristy; McGrath, Sean; Cottrell, Catherine E; Magrini, Vincent; Leonard, Jeffrey; Pindrik, Jonathan; Shaikhouni, Ammar; Boué, Daniel R; Thomas, Diana L; Pierson, Christopher R; Wilson, Richard K; Ostendorf, Adam P; Mardis, Elaine R; Koboldt, Daniel C.
Afiliación
  • Bedrosian TA; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Miller KE; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Grischow OE; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Schieffer KM; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • LaHaye S; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Yoon H; Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Miller AR; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Navarro J; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Westfall J; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Leraas K; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Choi S; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Williamson R; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Fitch J; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Kelly BJ; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • White P; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Lee K; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • McGrath S; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Cottrell CE; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Magrini V; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Leonard J; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Pindrik J; Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Shaikhouni A; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Boué DR; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Thomas DL; The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Pierson CR; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Wilson RK; Department of Neurosurgery, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Ostendorf AP; Department of Neurosurgery, The Ohio State University College of Medicine, Columbus, Ohio, USA.
  • Mardis ER; Department of Neurosurgery, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Koboldt DC; Department of Neurosurgery, The Ohio State University College of Medicine, Columbus, Ohio, USA.
Epilepsia ; 63(8): 1981-1997, 2022 08.
Article en En | MEDLINE | ID: mdl-35687047
ABSTRACT

OBJECTIVE:

Epilepsy-associated developmental lesions, including malformations of cortical development and low-grade developmental tumors, represent a major cause of drug-resistant seizures requiring surgical intervention in children. Brain-restricted somatic mosaicism has been implicated in the genetic etiology of these lesions; however, many contributory genes remain unidentified.

METHODS:

We enrolled 50 children who were undergoing epilepsy surgery into a translational research study. Resected tissue was divided for clinical neuropathologic evaluation and genomic analysis. We performed exome and RNA sequencing to identify somatic variation and we confirmed our findings using high-depth targeted DNA sequencing.

RESULTS:

We uncovered candidate disease-causing somatic variation affecting 28 patients (56%), as well as candidate germline variants affecting 4 patients (8%). In agreement with previous studies, we identified somatic variation affecting solute carrier family 35 member A2 (SLC35A2) and mechanistic target of rapamycin kinase (MTOR) pathway genes in patients with focal cortical dysplasia. Somatic gains of chromosome 1q were detected in 30% (3 of 10) of patients with Type I focal cortical dysplasia (FCD)s. Somatic variation in mitogen-activated protein kinase (MAPK) pathway genes (i.e., fibroblast growth factor receptor 1 [FGFR1], FGFR2, B-raf proto-oncogene, serine/threonine kinase [BRAF], and KRAS proto-oncogene, GTPase [KRAS]) was associated with low-grade epilepsy-associated developmental tumors. RNA sequencing enabled the detection of somatic structural variation that would have otherwise been missed, and which accounted for more than one-half of epilepsy-associated tumor diagnoses. Sampling across multiple anatomic regions revealed that somatic variant allele fractions vary widely within epileptogenic tissue. Finally, we identified putative disease-causing variants in genes not yet associated with focal cortical dysplasia.

SIGNIFICANCE:

These results further elucidate the genetic basis of structural brain abnormalities leading to focal epilepsy in children and point to new candidate disease genes.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Epilepsia / Malformaciones del Desarrollo Cortical Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Epilepsia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Asunto principal: Epilepsia / Malformaciones del Desarrollo Cortical Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Epilepsia Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos